Carvedilol and Embolism venous - a phase IV clinical study of FDA data

Summary:

Embolism venous is reported as a side effect among people who take Carvedilol (carvedilol), especially for people who are male, 60+ old, also take Spironolactone, and have Hiv infection.

The phase IV clinical study analyzes which people have Embolism venous when taking Carvedilol. It is created by eHealthMe based on reports of 110,224 people who have side effects when taking Carvedilol from the FDA, and is updated regularly.

What is Carvedilol?

Carvedilol has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 112,651 Carvedilol users. Check the latest studies of Carvedilol.

What is Embolism venous?

Embolism venous (embolus may pass into the arterial system) is found to be associated with 302 drugs and 394 conditions by eHealthMe. Check the latest studies of Embolism venous.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

110,224 people reported to have side effects when taking Carvedilol.
Among them, 13 people (0.01%) have Embolism venous.

Among these 13 people:

What is the gender of people who have Embolism venous when taking Carvedilol? *

female: 46.15 %
male: 53.85 %

What is the age of people who have Embolism venous when taking Carvedilol? *

What are other drugs people take besides Carvedilol? *

Spironolactone: 4 people, 30.77%
Belsomra: 3 people, 23.08%
Metoclopramide: 3 people, 23.08%
Isentress: 3 people, 23.08%
Epinastine Hydrochloride: 3 people, 23.08%
Tramadol: 3 people, 23.08%
Levofloxacin: 3 people, 23.08%
Celecoxib: 3 people, 23.08%
Famotidine: 3 people, 23.08%
Tabrecta: 3 people, 23.08%

What are other side effects people have besides Embolism venous? *

Oedema Peripheral (superficial swelling): 6 people, 46.15%
Blood Creatinine Increased: 4 people, 30.77%
Malignant Neoplasm Progression (cancer tumour came back): 3 people, 23.08%
Nausea (feeling of having an urge to vomit): 3 people, 23.08%
Dyspnea (difficult or laboured breathing): 3 people, 23.08%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 3 people, 23.08%
Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 3 people, 23.08%
Bacteriuria (presence of bacteria in urine): 3 people, 23.08%
Decreased Immune Responsiveness: 3 people, 23.08%
Face Oedema (swelling of face): 3 people, 23.08%

What are the existing conditions these people have? *

Non-Small Cell Lung Cancer Recurrent (type of epithelial lung cancer reoccurrence): 3 people, 23.08%
Hiv Infection: 3 people, 23.08%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 15.38%
Neuroendocrine Tumor: 2 people, 15.38%
Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 7.69%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 7.69%
Insomnia (sleeplessness): 1 person, 7.69%
Gout (uric acid crystals building up in the body): 1 person, 7.69%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 7.69%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Carvedilol and have Embolism venous?

- Check whether Embolism venous is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carvedilol:

Carvedilol (112,651 reports)

Embolism venous treatments and more:

Embolism venous (12,049 reports)

Browse all side effects of Carvedilol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Embolism venous:

Embolism venous (302 drugs)

Browse all the conditions that are associated with Embolism venous:

Embolism venous (394 conditions)

Related publications that referenced our studies

Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .
Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol (the active ingredients of Carvedilol) and Carvedilol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.